TWC
TGTX icon

TD Waterhouse Canada’s TG Therapeutics TGTX Stock Holding History

TD Waterhouse Canada’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.98K Buy
+37
New +$1.51K ﹤0.01% 2126
2024
Q4 		– Sell
-306
Closed -$6.99K – 2055
2024
Q3 		$6.99K Buy
+306
New +$6.68K ﹤0.01% 1421

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return

TD Waterhouse Canada's TGTX Position: Q2 2026 in Review

TD Waterhouse Canada opened a new position in TG Therapeutics (TGTX) in Q2 2026: 37 shares worth $1.98K. The stake represents ﹤0.01% of the portfolio and ranks #2126 among its holdings. This is a return to the name: TD Waterhouse Canada previously reported a position in TGTX as recently as Q3 2024.

TD Waterhouse Canada first reported a position in TGTX in Q3 2024 and has held it in 2 quarters since. The position peaked at $6.99K in Q3 2024. 431 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • TD Waterhouse Canada held 37 shares of TG Therapeutics worth $1.98K as of Q2 2026.
  • TG Therapeutics was a new TD Waterhouse Canada position in Q2 2026.
  • TG Therapeutics made up ﹤0.01% of TD Waterhouse Canada's portfolio in Q2 2026, its #2126 holding.
  • TD Waterhouse Canada first reported a position in TG Therapeutics in Q3 2024 and has held it in 2 quarters since.
  • TD Waterhouse Canada's TG Therapeutics position peaked at $6.99K in Q3 2024.
  • 431 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on TD Waterhouse Canada's 13F filing for Q2 2026, filed 27 Jul 2026.